NCT07064499Active, not recruiting
CGM Boosted by Artificial Intelligence for Better Glycaemic Control in T2 Diabetes
CGM Boosted by Artificial Intelligence for Better Glycaemic Control in T2 Diabetes: a Real-life Multicentre Observational Study in Belgium.
Source: ClinicalTrials.gov · Last updated 11 Aug 2025
Brief summary (registry, in English)
Title: CGM Boosted by Artificial Intelligence for better glycaemic control in T2 Diabetes : a real-life multicenter observational study in Belgium - MAGIC-T2D Background: In Belgium, since May 2023, reimbursement for continuous glucose monitoring systems has been extended to people with type 2 diabetes taking multiple injections of insulin. Despite the results of previous studies, the impact of this technology in terms of glycaemic control and patient-reported outcomes (PROMs) in real life for patients with type 2 diabetes is still unclear. Objective: To evaluate the impact of the CGMs on glycemic control and PROMs in people living with type 2 diabetes under real-life conditions. Methods and analysis: In a multicenter real-world observational study, more than 440 people with type 2 diabetes under multiple daily injection therapy who start to be monitored by a CGM in one of the 13 participating Belgian centers, will be followed for a period of 24 months. Outcomes: The primary and secondary endpoint are respectively the evolution of time spent in range (defined as a sensor glucose value between 70 and 180 mg/dL) and HbA1c from before start to 12 months after start of the CGM. Exploratory objectives will be studied using artificial intelligence (AI) to study glucose profiles to characterize the heterogeneity of type 2 diabetes.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 440 (estimated)
- First submitted
- 11 Jul 2025
- Start date
- 15 Dec 2023
- Primary completion date
- 31 Jul 2026
- Lead sponsor
- Erasme University Hospital
- Diseases
- Type 2 diabetes
- NCT number
- NCT07064499
What you commit to
- Study type: Observational
- Planned participants: 440
- From 15 Dec 2023 to the primary completion date, 31 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment that raises blood sugar levels (corticosteroids, etc.)
Other illness
- Secondary and type 1 diabetes
Other
- Dialysis
- Patient not able to sign the Informed Consent
Who the study is looking for
- Type 2 diabetes on MDI and starting CGM
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| HUB Hôpital Erasme Coordinator of this site? Confirm its status | Brussels | Belgium | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.